Aadil Najeed: In Many LMICs, Patients with Stage III NSCLC Cannot Access Durvalumab
Aadil Najeed/LinkedIn

Aadil Najeed: In Many LMICs, Patients with Stage III NSCLC Cannot Access Durvalumab

Aadil Najeed, Senior Resident at Government Medical College Srinagar, shared on LinkedIn:

“In many LMICs, patients with Stage III NSCLC cannot access durvalumab – not because it isn’t indicated, but because it is unaffordable.

Not a substitute for immunotherapy, but a question worth exploring: can we make cancer care more accessible?”

Commenting an older post:

“Adaptive SBRT boost after CCRT in Stage III NSCLC:

51 patients | 2-year OS: 61.5% | 2-year LRC: 62.8%.”

Title: Response-Adaptive Stereotactic Body Radiotherapy Boost After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC: A Prospective Single-Centre Cohort Study

Authors: Esin Kiraz, Celalettin Eroğlu, Mete Gündoğ, Oktay Bozkurt, Özgür Karabıyık, Ümmühan Abdülrezzak, Mustafa Tarkan Aksözen

Read the Article

You can also read:

Nikolaos A. Dallas: LiveWell Helps Us Build a More Accessible Lung Cancer Screening Pathway

Aadil Najeed: In Many LMICs, Patients with Stage III NSCLC Cannot Access Durvalumab